Coherus Oncology (CHRS) EBIT Margin (2013 - 2026)
Coherus Oncology (CHRS) reported EBIT Margin of 293.67% for Q1 2026, up 30424.0% on a YoY basis from N/an in Q1 2025, and up 18.4% sequentially from 359.9% in Q4 2025.
Coherus Oncology (CHRS) EBIT Margin (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 13 years of EBIT Margin data on file, last reported at 293.67% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 30424.0% year-over-year to 293.67%; the trailing twelve-month figure through Mar 2026 stood at 366.55% (up 19311.0% YoY), and the FY2025 full-year result was 429.51%, up 32706.0% from the prior year.
- EBIT Margin climbed to 293.67% in Q1 2026, from 359.9% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 42.92% in Q3 2023 to a low of 2937.05% in Q1 2024.
- A 5-year average of 449.74% and a median of 293.67% in 2026 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin sank 272819 bps in 2024 and surged 233914 bps in 2025, its largest moves.
- Tracing CHRS's EBIT Margin over 5 years: stood at 113.54% in 2022, then surged by 34 bps to 75.29% in 2023, then slumped by 680 bps to 586.89% in 2024, then jumped by 39 bps to 359.9% in 2025, then advanced by 18 bps to 293.67% in 2026.
- Business Quant data shows CHRS's EBIT Margin at 293.67% in Q1 2026, 359.9% in Q4 2025, and 383.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -293.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -293.67% |
| Dec 31, 2025 | -359.90% |
| Sep 30, 2025 | -383.14% |
| Jun 30, 2025 | -443.59% |
| Mar 31, 2025 | -597.91% |
| Dec 31, 2024 | -586.89% |
| Sep 30, 2024 | -774.22% |
| Jun 30, 2024 | -384.87% |
| Mar 31, 2024 | -2,937.05% |
| Dec 31, 2023 | -75.29% |
| Sep 30, 2023 | -42.92% |
| Jun 30, 2023 | -58.83% |
| Mar 31, 2023 | -208.86% |
| Dec 31, 2022 | -113.54% |
| Sep 30, 2022 | -177.11% |
| Jun 30, 2022 | -73.17% |
| Mar 31, 2022 | -134.62% |
| Dec 31, 2021 | -53.91% |
| Sep 30, 2021 | -39.74% |
| Jun 30, 2021 | -27.57% |